OverviewSuggest Edit

Merrimack is a fully integrated biopharmaceutical company that views cancer as a complex engineering challenge. Through systems biology, which brings together the fields of biology, computing and engineering, Merrimack aims to decrease uncertainty in drug development and clinical validation, and move discovery efforts beyond trial and error. Such an approach has the potential to make individualized treatment of patients a reality. Merrimack's first commercial product, ONIVYDETM (irinotecan liposome injection), was approved by the U.S. FDA and with four additional candidates in clinical studies, several in preclinical development and multiple biomarkers designed to support patient selection, the Company is building one of the most robust oncology pipelines in the industry.

TypePublic
Founded2000
HQCambridge, US
Websitemerrimack.com
Employee Ratings2.6

Latest Updates

Employees (est.) (Feb 2019)27(-62%)
Revenue (FY, 2016)$144.3 M(+62%)
Share Price (Mar 2019)$7.1 (-2%)

Key People/Management at Merrimack Pharmaceuticals

Richard Peters

Richard Peters

President and Chief Executive Officer

Merrimack Pharmaceuticals Office Locations

Merrimack Pharmaceuticals has an office in Cambridge
Cambridge, US (HQ)
One Kendall Square, Binney St
Show all (1)
Report incorrect company information

Merrimack Pharmaceuticals Financials and Metrics

Merrimack Pharmaceuticals Revenue

Merrimack Pharmaceuticals's revenue was reported to be $144.27 m in FY, 2016 which is a 61.6% increase from the previous period.
USD

Net income (FY, 2018)

(40.5m)

Market capitalization (18-Mar-2019)

94.5m

Closing stock price (18-Mar-2019)

7.1

Cash (31-Dec-2018)

20.1m

EV

89.3m
Merrimack Pharmaceuticals's current market capitalization is $94.5 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

47.8m102.8m89.3m144.3m

Revenue growth, %

115%(13%)62%

Cost of goods sold

6.9m

Gross profit

137.4m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

Revenue

21.3m33.7m28.1m

Cost of goods sold

1.9m1.0m

Gross profit

31.8m27.1m

Gross profit Margin, %

94%96%
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

65.1m35.7m185.6m21.5m93.4m20.1m

Accounts Receivable

5.9m3.3m6.5m17.5m100.0k

Inventories

5.5m4.7m3.7m14.6m

Current Assets

166.6m132.1m201.4m57.4m95.0m76.1m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

Cash

105.5m66.9m77.8m100.3m28.8m33.7m56.4m48.2m21.5m36.5m17.2m135.5m107.2m34.3m22.5m

Accounts Receivable

8.8m12.2m6.6m2.6m4.2m1.8m2.1m15.6m19.3m22.2m43.0k43.0k190.0k

Inventories

8.1m12.3m14.8m

Current Assets

200.3m138.9m103.8m162.1m99.3m74.9m70.9m160.7m119.0m89.6m46.3m141.6m115.6m77.1m61.7m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(130.7m)(83.6m)(147.8m)(153.5m)470.9m(40.5m)

Depreciation and Amortization

2.6m3.2m4.3m6.2m5.2m4.1m

Inventories

4.0m827.0k(3.7m)(9.7m)

Accounts Payable

Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

Net Income

(98.3m)(27.8m)(46.0m)(74.1m)(34.4m)(57.3m)(99.7m)(38.7m)(89.6m)(119.9m)(30.2m)480.7m483.8m(17.8m)(35.6m)

Depreciation and Amortization

1.9m886.0k2.2m2.8m2.1m4.3m1.5m3.0m5.2m1.2m2.1m2.8m1.2m2.3m

Inventories

(4.4m)(8.4m)(10.7m)

Cash From Operating Activities

(67.7m)(31.4m)(64.2m)(3.1m)(59.7m)(102.0m)(53.5m)(104.4m)(139.3m)(10.2m)(95.5m)(121.1m)(17.3m)(33.6m)
USDY, 2018

EV/CFO

-1.4 x

Financial Leverage

1.5 x
Show all financial metrics
Report incorrect company information

Merrimack Pharmaceuticals Online and Social Media Presence

Embed Graph
Report incorrect company information

Merrimack Pharmaceuticals News and Updates

Report incorrect company information

Merrimack Pharmaceuticals Frequently Asked Questions

  • When was Merrimack Pharmaceuticals founded?

    Merrimack Pharmaceuticals was founded in 2000.

  • Who are Merrimack Pharmaceuticals key executives?

    Merrimack Pharmaceuticals's key executives are Richard Peters.

  • How many employees does Merrimack Pharmaceuticals have?

    Merrimack Pharmaceuticals has 27 employees.

  • Who are Merrimack Pharmaceuticals competitors?

    Competitors of Merrimack Pharmaceuticals include Heidelberg Pharma, MEI Pharma and Oncopeptides.

  • Where is Merrimack Pharmaceuticals headquarters?

    Merrimack Pharmaceuticals headquarters is located at One Kendall Square, Binney St, Cambridge.

  • Where are Merrimack Pharmaceuticals offices?

    Merrimack Pharmaceuticals has an office in Cambridge.

  • How many offices does Merrimack Pharmaceuticals have?

    Merrimack Pharmaceuticals has 1 office.